Lyon: IARC Press 2008. 2. Horny H-P, Sotlar K, Valent P, Hartmann K:Mastocytosis—a disease of the hematopoietic stem cell [Die Mastozytose – Eine Erkrankung der hämopoetischen Stammzelle].

In September of 2000, the world's leading experts in MC met to discuss and present data at the "Year 2000 Working Conference on Mastocytosis," held in Vienna, Austria. Table 1 presents a uniform ...

H2 antihistamines, such as ranitidine, cimetidine, or famotidine, are used to treat gastric hypersecretion and peptic ulcer disease associated with histamine release in mastocytosis (Worobec ...

Consequently, these criteria are not suitable for determining systemic mastocytosis as a result ... yield negative results even in patients whose disease matches the remaining WHO criteria ...

The following is a summary of "Comparison of prognostic scores according to WHO classification in 170 patients with advanced ...

This finding suggests that these autoantibodies do not have a substantial role in systemic mastocytosis disease pathogenesis or manifestations. “On the basis of . . . findings indicating that ...

MCAS is a related disease of systemic mastocytosis, but it is not one of its subtypes. It is a non-cancerous condition ...

Mastocytosis is a rare disorder that develops when the immune system overproduces mast cells—a type of white blood cell that plays an important role in your body's inflammatory process and helps ...

In Systemic Mastocytosis, What’s the Impact of Type ... in the serum of patients with systemic mastocytosis are markers of disease severity. These findings suggest that analyzing a panel of ...

Cogent Biosciences' uncertain competitive edge may compel investors to sit on the sidelines. Read more about the cautious ...

Sep. 20, 2024 — The incidence of stroke continues to increase for adults and children living with sickle cell disease (SCD) despite the Stroke Prevention Trial in ... Sep. 13, 2024 — When a ...